Summary
- Profile Type
- Technology offer
- POD Reference
- TOIT20230918009
- Term of Validity
- 19 September 2023 - 18 September 2025
- Company's Country
- Italy
- Type of partnership
- Investment agreement
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- An Italian medical research centre committed to healthcare and translational medicine has developed a new monoclonal antibody that specifically identifies the male ribosomal protein RPS4Y1 and distinguishes male from female cells. The medical research centre is looking for an industrial partner in the healthcare sectors interested in license agreements.
- Full Description
-
Prenatal diagnosis can be very important for pregnant women carriers of X-linked recessive congenital disorders, such as Haemophilia, Fragile X syndrome or Duchenne muscular dystrophy. In case of a male foetus at risk, conventional invasive diagnostic procedures such as chorionic villus sampling and amniocentesis, with an associated risk of miscarriage, are used to identify in foetuses the maternally inherited genetic defect. The availability of a non-invasive prenatal diagnosis test that can safely identify the affected male foetuses in the early period of gestation is still an unsolved problem, due to the poor circulating DNA quantity, the high maternal DNA contamination, and the lack of specific foetal markers.
The developed monoclonal antibody specifically binds the RPS4Y1 protein, a gender (male) biomarker, synthesized by a gene localized in the Y chromosome. The identification of that protein in biological samples, especially in blood, could overcome the current limit of lack of specific foetal markers and could improve the identification of foetal cells by targeting any type of male cells circulating in the maternal blood, thus allowing the development of a rapid and non-invasive method to select male cells for the genetic analysis. The antibody is proposed to be used in prenatal diagnostic tests of X-linked disorders to isolate male foetal cells from a blood sample taken from the mother since the early weeks of pregnancy. - Advantages and Innovations
-
• Male cells identification and selection.
• Non invasive prenatal diagnosis of X-linked diseases.
• Overcome the lack of specific fetal marker for the unambiguous identification of (male) fetal cells circulating in the maternal blood.
• Improve the isolation of (male) fetal cells for the non-invasive prenatal diagnosis.
• Avoid miscarriages associated to conventional invasive diagnostic procedures (chorionic villus sampling and amniocentesis). - Stage of Development
- Lab tested
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- Patent application filed in Italy and USA
Partner Sought
- Expected Role of a Partner
- The medical research centre is interested in licensing opportunities. Through technology licensing, the industrial partner will further develop and exploit the technology according to the licensing agreement
- Type and Size of Partner
- SME 50 - 249
- Big company
- Type of partnership
- Investment agreement
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001006 - Prenatal diagnostic
- Targeted countries
- All countries